Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

PURPOSE: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phas...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Hughes, Timothy, Saglio, Giuseppe, Branford, Susan, Soverini, Simona, Kim, Dong-Wook, Müller, Martin C., Martinelli, Giovanni, Cortes, Jorge, Beppu, Lan, Gottardi, Enrico, Kim, Dongho, Erben, Philipp, Shou, Yaping, Haque, Ariful, Gallagher, Neil, Radich, Jerald, Hochhaus, Andreas
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979230/
https://ncbi.nlm.nih.gov/pubmed/19652056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.21.8230
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items